February 4, 2016
LOVE IS IN THE AIR!
Phase III Trial to Begin of IVIG Product to Treat PI
As a leader in our industry, CHS works diligently to stay current on new products and trends in our markets. In October, the U.S. Food and Drug Administration cleared the investigational new drug application for ProMetic Life Sciences’ intravenous immune globulin (IVIG) product for the treatment of primary immunodeficiency disease (PI). The Phase III clinical trial, which was slated to begin in the fourth quarter of 2015, is an open-label, single-arm, two cohort multicenter study to investigate the safety, tolerability, efficacy and pharmacokinetics of ProMetic’s plasma-purified IVIG in a total of 75 patients with PI, including 50 adults (cohort one) and 25 children (cohort two).
ProMetic utilizes a proprietary platform, the Plasma Protein Purification System
(PPPS), a multi-product sequential purification process originally developed in collaboration with the American Red Cross that employs powerful affinity separation materials in a multi-step process to extract and purify plasma proteins in high yields. “The yield advantage provided by our PPPS technology for more mainstream plasmaderived products such as IVIG is of great importance to our commercial strategy,” said Pierre Laurin, president and chief executive officer of ProMetic. “The significant financial contribution from products like IVIG will greatly facilitate the pursuit of our strategy, namely the development of much needed and more affordable orphan products addressing rare diseases.”
CHS will continue to monitor the progress of this new IVIG product.
Jolin D. McCleskey
Executive Vice President
- Distribution of Valentine's Day Goodies
- Annual meeting with CHS & NCPC- April 6, 2016
- Planning is under way for creative ways to celebrate the NCPC Staff, our infusion patients, and our referral sources... watch as we Ring in Spring, a HOT Summer kick-off, Patient Appreciation Month and much more!!